OneSource Specialty Valuation Multiples

OneSource Specialty Overview

About OneSource Specialty

OneSource Specialty Pharma Ltd is engaged in the research, development, manufacture and commercialization of biological drug products in different injectable formats. The company also offers end-to-end CDMO services across all phases of pre-clinical and clinical development and commercial supply of biologics. The company’s reportable segments are CDMO (Contract Development and Manufacturing Organization (CDMO) : Development and manufacture of pharmaceutical products and associated services); and Unit-3 Multimodal Facility and CDMO-2.

Founded

2007

HQ

Employees

1.3K

Website

onesourcecdmo.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $158M

EBITDA: $39M

EV

$2B

Valuation Multiples

Multiples.vc

Start free trial

OneSource Specialty Financials

OneSource Specialty reported last 12-month revenue of $158M and EBITDA of $39M.

In the same LTM period, OneSource Specialty generated $113M in gross profit, $39M in EBITDA, and $5M in net income.

OneSource Specialty P&L

In the most recent fiscal year, OneSource Specialty reported revenue of $169M and EBITDA of $55M.

OneSource Specialty expects next 12-month revenue of XXX and NTM EBITDA of XXX

OneSource Specialty Stock Performance

OneSource Specialty has current market cap of $2B, and enterprise value of $2B.

OneSource Specialty's stock price is $14.86.

OneSource Specialty Valuation Multiples

OneSource Specialty trades at 11.6x EV/Revenue multiple, and 46.4x EV/EBITDA.

OneSource Specialty Financial Valuation Multiples

As of April 10, 2026, OneSource Specialty has market cap of $2B and EV of $2B.

Equity research analysts estimate OneSource Specialty's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

OneSource Specialty has a P/E ratio of 310.3x.

OneSource Specialty Margins & Growth Rates

OneSource Specialty's revenue in the last 12 month grew by 59%.

OneSource Specialty's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.

OneSource Specialty's rule of 40 is 79% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

OneSource Specialty's rule of X is 145% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

OneSource Specialty Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

OneSource Specialty M&A Activity

OneSource Specialty acquired XXX companies to date.

Last acquisition by OneSource Specialty was on XXXXXXXX, XXXXX. OneSource Specialty acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

OneSource Specialty Investment Activity

OneSource Specialty invested in XXX companies to date.

OneSource Specialty made its latest investment on XXXXXXXX, XXXXX. OneSource Specialty invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).